{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:41:27Z","timestamp":1761986487342},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":1939,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1186\/s40413-014-0050-z","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T19:27:16Z","timestamp":1419967636000},"page":"72","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review"],"prefix":"10.1016","volume":"7","author":[{"given":"Diana C.","family":"Carrillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Sanchez","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Egea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos D.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1186\/s40413-014-0050-z_bib0005","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199506293322608","article-title":"Chronic urticaria","volume":"332","author":"Greaves","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1186\/s40413-014-0050-z_bib0010","first-page":"214","article-title":"Epidemiology of urticaria in Spain","volume":"14","author":"Gaig","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"10.1186\/s40413-014-0050-z_bib0015","first-page":"715","article-title":"Chronic Urticaria: Omalizumab and Review of Therapeutic Options","volume":"12","author":"Bergstrom","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1186\/s40413-014-0050-z_bib0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1346-8138.2007.00276.x","article-title":"Chronic idiopathic urticaria: prevalence and clinical course","volume":"34","author":"Kulthanan","year":"2007","journal-title":"J Dermatol"},{"issue":"6","key":"10.1186\/s40413-014-0050-z_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4168\/aair.2012.4.6.357","article-title":"Effects of omalizumab treatment in patients with refractory chronic urticaria","volume":"4","author":"Nam","year":"2012","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"10.1186\/s40413-014-0050-z_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.iac.2013.09.012","article-title":"Chronic Spontaneous Urticaria: Etiology and Pathogenesis","volume":"34","author":"Saini","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1186\/s40413-014-0050-z_bib0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"issue":"7","key":"10.1186\/s40413-014-0050-z_bib0040","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/all.12370","article-title":"Methods report on the development of the 2013 revision and update of the EAACI\/GA2 LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"issue":"1","key":"10.1186\/s40413-014-0050-z_bib0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ad.2013.06.002","article-title":"Omalizumab in the treatment of chronic urticaria","volume":"105","author":"Franc\u00e9s","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"10.1186\/s40413-014-0050-z_bib0050","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5021\/ad.2013.25.2.242","article-title":"A long term case series study of the effect of omalizumab on chronic spontaneous urticaria","volume":"25","author":"Lef\u00e9vre","year":"2013","journal-title":"Ann Dermatol"},{"issue":"6","key":"10.1186\/s40413-014-0050-z_bib0055","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1186\/s40413-014-0050-z_bib0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACI.0000000000000083","article-title":"Biologic agents and the therapy of chronic spontaneous urticaria","volume":"14","author":"Kaplan","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1186\/s40413-014-0050-z_bib0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1186\/s40413-014-0050-z_bib0070","first-page":"426","article-title":"Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL)","volume":"18","author":"Valero","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"10.1186\/s40413-014-0050-z_bib0075","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1398-9995.2008.01920.x","article-title":"The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings","volume":"64","author":"Mlynek","year":"2009","journal-title":"Allergy"},{"key":"10.1186\/s40413-014-0050-z_bib0080","unstructured":"Medical Search Terms Omalizumab [Available from: https:\/\/www.dropbox.com\/s\/8hhaisftmbxx4iy\/search_strategy_%283%29%5B1%5D.pdf?dl=0]"},{"key":"10.1186\/s40413-014-0050-z_bib0085","unstructured":"Higgins J, Green S: Manual Cochrane de revisiones sistem\u00e1ticas de intervenciones. [Available from: http:\/\/es.cochrane.org\/sites\/es.cochrane.org\/files\/uploads\/Manual_Cochrane_510_reduit.pdf]"},{"issue":"3","key":"10.1186\/s40413-014-0050-z_bib0090","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1186\/s40413-014-0050-z_bib0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1186\/s40413-014-0050-z_bib0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1186\/s40413-014-0050-z_bib0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine\u2013refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1186\/s40413-014-0050-z_bib0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1186\/s40413-014-0050-z_bib0115","doi-asserted-by":"crossref","unstructured":"Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, Bulbul Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Ros\u00e9n K: Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic\/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.J Invest Dermatol 2014, in press.,","DOI":"10.1038\/jid.2014.512"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40413-014-0050-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40413-014-0050-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455119302376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455119302376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40413-014-0050-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40413-014-0050-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T15:47:21Z","timestamp":1556120841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455119302376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":23,"alternative-id":["S1939455119302376"],"URL":"https:\/\/doi.org\/10.1186\/s40413-014-0050-z","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]},"article-number":"72"}}